Concurrent Investment Advisors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$491K Buy
2,272
+50
+2% +$9.56K ﹤0.01% 1413
2026
Q1
$407K Sell
2,222
-2,154
-49% -$397K ﹤0.01% 1315
2025
Q4
$770K Buy
4,376
+2,804
+178% +$458K 0.01% 947
2025
Q3
$220K Buy
+1,572
New +$212K ﹤0.01% 1303
2024
Q4
– Sell
-3,340
Closed -$647K – 1135
2024
Q3
$647K Sell
3,340
-46
-1% -$9.62K 0.02% 563
2024
Q2
$785K Buy
3,386
+389
+13% +$84.5K 0.03% 489
2024
Q1
$646K Buy
2,997
+1,567
+110% +$367K 0.03% 479
2023
Q4
$370K Buy
+1,430
New +$351K 0.02% 576

Other funds holding BIIB

Concurrent Investment Advisors's BIIB Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Biogen (BIIB) stake by 2.3% in Q2 2026, buying an estimated $9.56K and bringing the position to 2,272 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

Concurrent Investment Advisors first reported a position in BIIB in Q4 2023 and has held it in 8 quarters since. The position peaked at $785K in Q2 2024. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Concurrent Investment Advisors held 2,272 shares of Biogen worth $491K as of Q2 2026.
  • Concurrent Investment Advisors bought 50 Biogen shares in Q2 2026, an estimated $9.56K.
  • Biogen made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1413 holding.
  • Concurrent Investment Advisors first reported a position in Biogen in Q4 2023 and has held it in 8 quarters since.
  • Concurrent Investment Advisors's Biogen position peaked at $785K in Q2 2024.
  • 1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.